SCYNEXIS Inc.

06/11/2021 | Press release | Distributed by Public on 06/11/2021 06:33

SCYNEXIS to Present at the BIO Digital International Convention 2021

  • Company presentation will highlight BREXAFEMME® (ibrexafungerp tablets), the first FDA-approved product in the ibrexafungerp development pipeline, in addition to ongoing programs in the hospital setting